GLP-1 / GIP / Glucagon Triple Agonist
The most scientifically sophisticated entry point in the Eterna Femme system — a single peptide with three receptor activations, engineered to support metabolic function, satiety signaling, and energy regulation in women navigating perimenopause. Research-Backed. California-Manufactured.
The Science
Retatrutide activates three key metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triad targets appetite regulation, insulin sensitivity, and energy expenditure in parallel — making it meaningfully more comprehensive than GLP-1 monotherapy alone. The three-receptor activation drives additive rather than merely synergistic metabolic effects.
Estrogen decline reshapes how the body stores fat, regulates glucose, and processes hunger signals. GLP-1 receptor density shifts, insulin sensitivity changes, and the default metabolic state moves toward higher visceral fat accumulation and reduced satiety signaling. Retatrutide's triple mechanism addresses these shifts directly — not by replacing what estrogen did, but by working on the receptor systems that remain active and responsive.
Retatrutide emerged from Eli Lilly's Phase 2 clinical program as one of the most promising agents in the GLP-1/GIP/glucagon triad class. Published Phase 2 data showed meaningful weight reduction and metabolic improvements at multiple dose levels. Eterna Femme frames this as a research-supervised peptide approach — appropriate candidates have access to the underlying science and ongoing monitoring throughout their program.
Peptide approaches work through sustained signaling, not acute intervention. Retatrutide requires consistent engagement and ongoing clinical oversight to realize its effects. For women who want a single injection to solve a complex metabolic challenge, this is not the right framework. For women who understand that meaningful metabolic support requires a sustained commitment — this is a product built for exactly that orientation.
Who It's For
Retatrutide is not a general weight-loss product. It is a research-supervised peptide approach for women whose metabolic function has measurably shifted — and who want a science-backed framework to work with those changes.
You are navigating metabolic shifts driven by estrogen decline — changes that affect how your body processes hunger signals, stores fat, and regulates energy. this approach is built for that biology, not adapted from it.
Your body has changed in ways that diet and exercise alone aren't fully addressing. Retatrutide works on the signaling pathways that regulate appetite and metabolic rate — not just the behavioral layer.
You want support that works with your body's actual mechanisms — not a shortcut that depletes what you're already running low on. Sustained engagement matters more to you than dramatic short-term results.
Retatrutide is positioned as a lifestyle commitment, not a rapid intervention. the approach is designed for women who understand that metabolic health requires consistent, research-supervised engagement — and who want a clinical framework that respects that complexity.
Why Eterna Femme
Every peptide is manufactured in California, USA — not sourced from undifferentiated international suppliers. U.S. manufacturing means quality-assured synthesis with full supply chain visibility.
Retatrutide's mechanisms don't work the same way in a perimenopausal body as they do in a 25-year-old male. Our clinical framework accounts for the hormonal context — not just the peptide's documented effects.
Every candidate goes through a clinical intake evaluation. Retatrutide candidacy is not assumed — the intake review determines fit. This is not a product you add to a cart. It is an approach you apply for.
What the published research shows
Retatrutide research covers GLP-1, GIP and glucagon receptor activation, downstream effects on satiety and energy expenditure, and the open questions that remain. The Research Library brings together the primary studies so you can read them yourself before forming a view.
What the published research shows — read the science.